Who We Are

Delivering on our promise for patients

Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

We are led by an experienced international management team. Our proprietary product pipeline and next-generation antibody technologies are the result of our strong company culture and a deep passion for innovation. We are inspired by nature and the power of the immune system to transform cancer treatment.

Button

Board of Directors

Guiding a prosperous tomorrow

The Genmab Board of Directors is composed of a diverse group of industry experts with a deep understanding in life sciences and corporate governance. As current or former chief executive officers, presidents and leaders in their respective fields, our board of directors offers Genmab extensive experience from international research-based organizations, including leading biotech and pharmaceutical companies.

The Genmab Board of Directors meets several times a year for ordinary or extraordinary meetings. Board duties include overseeing the business strategy, accounting practices, executive compensation, corporate governance practices and the appointment of executive officers. The Board of Directors has established four committees: the Compensation Committee, the Audit and Finance Committee, the Scientific Committee and the Nominating and Corporate Governance Committee.

In accordance with the articles of association, the Board of Directors is elected partly by the Annual General Meeting (AGM) and partly by Genmab employees. Board members elected by the AGM are elected for a period of one year whereas board members elected by Genmab employees are elected for a period of three years. Members may stand for re-election for successive terms. The Board of Directors shall consist of not less than three and no more than nine members; and is currently comprised of nine members including three employee representatives.

The business address for the members of the Board of Directors is c/o Genmab A/S, Kalvebod Brygge 43, 1560 Copenhagen V, Denmark.

Gender Target Figure

Target Figure for Women in the Board of Directors of Genmab A/S

At the General Meeting of Genmab A/S, the Board of Directors proposes election of the most suitable candidates based on, amongst other criteria, the skill set requirements for board of directors of biotech companies. In connection with the proposals for election, the Board of Directors takes into consideration the opportunity to propose election of candidates that may secure gender equality to the Board of Directors for the long term.

In March 2017, Genmab achieved its target figure for women in the Board of Directors according to which it was the aim of the Board of Directors that the proportion of female board members elected by the General Meeting was increased to at least 25%. Considering the Board of Directors’ current composition, which constitutes equitable gender representation cf. guidelines from the Danish Business Authority, it is the aim of the Board of Directors to maintain an equitable gender representation in the Board of Directors.

The target figure may be amended by the Board of Directors and should be interpreted in accordance with applicable equal rights and anti-discrimination legislation in Denmark, in force from time to time.




Learn more about our board members by clicking on their names.

Deirdre P. Connelly

Board Chair

Independent

Elected by: General Meeting

First elected: 2017
Current term expires: 2021

Committee Positions

Chair: Compensation

Member: Audit & Finance, Nominating & Corporate Governance

Nationality

Hispanic/American

Born

October 1960

Special Competencies

More than 30 years’ experience as a corporate leader and extensive experience in corporate governance as a board member. Comprehensive experience with business turnaround, corporate culture transformation, product launch and talent development. Successfully directed the launch of more than 20 new pharmaceutical drugs. Former President, North America Pharmaceuticals for GlaxoSmithKline.

Current Board Positions

Member: Macy’s Inc. and Lincoln National Corporation

Pernille Erenbjerg

Deputy Chair

Independent
Elected by: General Meeting
First elected: 2015
Current term expires: 2021

Committee Positions

Chair: Audit & Finance Committee
Member: Nominating & Corporate Governance

Nationality

Danish

Born

August 1967

Special Competencies

Senior executive management and broad business experience from the telecoms, media and tech industries. Extensive experience with transformation of large and complex companies, including digital transformations and digitally based innovation. Comprehensive all-around background within finance, including extensive exposure to stock markets, equity and debt investors. Certified Public Accountant background (no longer practicing). Responsible for major transformation processes in complex organizations including M&A. Former CEO and President of TDC A/S. Due to her experience and background within accounting, Pernille Erenbjerg qualifies as an audit committee financial expert.

Current Board Positions

Deputy Chair: Millicom
Member: Nordea AB, GlobalConnect/IP-Only
Audit Committee Member: Nordea AB
Chair of Remuneration Committee: Millicom
Audit Committee Member: Millicom, Nordea AB
Operations and Sustainability Committee Member: Nordea AB

Anders Gersel Pedersen, M.D., Ph.D.

Board Member

Non-independent
Elected by: General Meeting
First elected: 2003
Current term expires: 2021

Committee Positions

Chair: Nominating & Corporate Governance
Member: Scientific, Compensation

Nationality

Danish

Born

September 1951

Special Competencies

Business and management experience in the pharmaceutical industry, including expertise in clinical research, development, regulatory affairs and product life cycle management. Former Executive Vice President of Research & Development of H. Lundbeck A/S.

Current Board Positions

Chairman: Aelis Farma S.A.S.
Deputy Chairman: Bavarian Nordic A/S
Member: Hansa Medical AB, Bond 2 Development 2 GP Limited

Paolo Paoletti, M.D.

Board Member

Independent
Elected by: General Meeting
First elected: 2015
Current term expires: 2021

Committee Positions

Chair: Scientific
Member: Compensation

Nationality

Italian (U.S. Citizen)

Born

October 1950

Special Competencies

Extensive experience in research, development and commercialization in the pharmaceutical industry. Successfully conducted submissions and approvals of new cancer drugs and new indications in the U.S. and in Europe. Responsible for seven new medicines for cancer patients during his 10 years at GlaxoSmithKline and one new cancer medicine during his time at Eli Lilly.

Current Position, including Managerial Positions

Acting CEO for GammaDelta Therapeutics Limited

Current Board Positions

Member: PsiOxus Therapeutics Limited, FORMA Therapeutics

Rolf Hoffmann

Board Member

Independent
Elected by: General Meeting
First elected: 2017
Current term expires: 2021

Committee Positions

Member: Audit & Finance, Scientific

Nationality

German

Born

May 1959

Special Competencies

Extensive international management experience with expertise in creating and optimizing commercial opportunities in global markets. Additional expertise in P&L management, governance and Corporate Integrity Agreement Management, compliance and organizational efficiency. Over 20 years’ experience in the international pharmaceutical and biotechnology industries at Eli Lilly and Amgen.

Current Position, including Managerial Positions

Adjunct Professor Strategy and Entrepreneurship, University of North Carolina Business School

Current Board Positions

Chairman: Biotest AG
Member: Trizell Ltd., EUSA Pharma, Inc., Paratek Pharmaceuticals, Inc. and Shield Therapeutics plc

Jonathan Peacock

Board Member

Independent
Elected by: General Meeting
First elected: 2020
Current term expires: 2021

Committee Positions

Member: Audit & Finance, Compensation

Nationality

British

Born

March 1958

Special Competencies

Extensive experience in corporate finance, strategy and international expansion in the pharmaceutical industry. Involved in several large and small acquisitions and partnerships of commercial, pipeline and research assets covering diverse global markets as CFO at Novartis Pharma and CFO at Amgen. Jonathan Peacock holds a degree in Economics, is a chartered accountant and has a background as a partner at McKinsey and Price Waterhouse.

Current Board Positions

Chairman: Bellerophon Therapeutics Inc
Member: Avantor Inc, W20 Group, Socati Corporation, Natural History Museum of Los Angeles

Peter Storm Kristensen

Board Member

Non-independent
Elected by: Employees
First elected: 2016
Current term expires: 2022

Nationality

Danish

Born

November 1974

Special Competencies

Broad legal experience within the pharmaceutical industry with specialty in corporate law, securities law, human resources law as well as drafting and negotiating contracts in general.

Current Position, including Managerial Positions

Associate Director, Legal at Genmab

Mijke Zachariasse, Ph.D.

Board Member

Non-independent
Elected by: Employees
First elected: 2019
Current term expires: 2022

Nationality

Dutch

Born

August 1973

Special Competencies

Broad experience in people and business management in the natural sciences sector. Specific expertise in building strategic partnerships across sectors, financial and fund management, and setting research strategies in the academic sector.

Current Position, including Managerial Positions

Director, Protein Production and Chemistry at Genmab

Rima Bawarshi Nassar, Ph.D.

Board Member

Non-independent
Elected by: Employees
First elected: 2019
Current term expires: 2022

Nationality

Palestinian-Lebanese (U.S. Citizen)

Born

December 1953

Special Competencies

Extensive expertise in global regulatory affairs and solid understanding and knowledge of drug research and development. Over 30 years’ experience in international pharmaceutical and biotechnology industries in various therapeutic areas and roles. Successful product submissions and approvals with optimal labeling. Experience in strategic leadership, management, and talent development.

Current Position, including Managerial Positions

Vice President, Head of Global Regulatory Affairs – Oncology

Committee Composition

Board Diversity and Skills Matrix

Basic InformationCore SkillsSector-Specific Skills
DirectorBornGender and NationalityLife Science
Industry
Executive
Experience
Financial/
Risk
Legal/
Governance
IT/
Cybertech
Environmental/
Sustainability
International
Markets

Employee ElectedSwipe to view moreScroll to view more

Want to get the latest stock information and news about Genmab?

Start here

  • Sound corporate governance

    Our corporate governance is at the center of everything we do

    Learn more

  • Being socially responsible

    We are building a sustainable company through business-driven CSR

    Learn about our CSR

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.